| Autor: |
van den Berg J; Department of Obstetrics and Gynaecology, Canisius-Wilhelmina Hospital , Nijmegen , The Netherlands., Hamel CC; Department of Obstetrics and Gynaecology, Canisius-Wilhelmina Hospital , Nijmegen , The Netherlands., Coppus SF; Department of Obstetrics and Gynaecology, Maxima Medical Centre , Eindhoven , The Netherlands., Snijders MP; Department of Obstetrics and Gynaecology, Canisius-Wilhelmina Hospital , Nijmegen , The Netherlands., Vandenbussche FP; Department of Obstetrics and Gynaecology, Radboud University Nijmegen Medical Centre , Nijmegen , The Netherlands. |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology [J Obstet Gynaecol] 2019 Oct; Vol. 39 (7), pp. 1006-1011. Date of Electronic Publication: 2019 Jun 19. |
| DOI: |
10.1080/01443615.2019.1602598 |
| Abstrakt: |
To investigate the current and future addition of mifepristone to misoprostol treatment in case of early pregnancy failure (EPF), a digital questionnaire was distributed to a representative sample of all Dutch hospitals (25/79). In non-teaching centres, the presence of a local protocol was significantly lower compared to academic and teaching hospitals ( p =.012). If a local protocol was present, the first choice of treatment was medical in 54.5%. Four respondents (16%) always prescribed mifepristone in case of EPF. The most common reason not prescribing mifepristone was the lack of sufficient scientific evidence. An average increase in success rate of 21.7% was desired to prescribe mifepristone in the future for EPF. Completeness of evacuation of products of conception from the uterus was usually assessed after 1 week by ultrasonography combined with clinical signs. If a complete evacuation was not achieved by the initial medical treatment, expectant management was proposed just as often as surgical intervention. Impact Statement What is already known on this subject? In case of early pregnancy failure (EPF), women can choose from both expectant medical (misoprostol, whether or not combined with mifepristone) and surgical (D and C) treatment. In The Netherlands, a national guideline concerning the treatment of EPF is still lacking. A questionnaire performed by Verschoor et al. ( 2014 ) showed there was a large practice variety between Dutch clinics. What the results of this study add? In this study, a representative sample of all Dutch clinics received a questionnaire about the treatment of EPF. The results confirm a large practice variation regarding treatment of EPF. The first choice of treatment, the medical treatment regimen, and the assessment of whether or not the treatment have been variations of successful between clinics. With regards to the addition of mifepristone to the medical treatment regime with misoprostol, gynaecologists are willing to consider mifepristone if an improvement of efficacy of approximately 20% is scientifically proven. What the implications are of these findings for clinical practice and/or further research? In our opinion, these results emphasise the need for a national guideline concerning the treatment of EPF. Our results also demonstrate that, if the addition of mifepristone to medical treatment with misoprostol proves to be more efficient than misoprostol alone, gynaecologists are willing to prescribe mifepristone in the future. Whether the addition is indeed more effective than misoprostol alone, will be the subject of a multicentre, double-blind, placebo-controlled randomised controlled trial, planned to begin in the first half of 2018. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
